Kamel Laribi

5.0k total citations · 1 hit paper
62 papers, 1.2k citations indexed

About

Kamel Laribi is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Kamel Laribi has authored 62 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 27 papers in Genetics and 23 papers in Pathology and Forensic Medicine. Recurrent topics in Kamel Laribi's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Acute Myeloid Leukemia Research (15 papers). Kamel Laribi is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Acute Myeloid Leukemia Research (15 papers). Kamel Laribi collaborates with scholars based in France, United States and Spain. Kamel Laribi's co-authors include Alix Baugier de Materre, Brian G.M. Durie, Kazuyuki Shimizu, G. David Roodman, Ramón García‐Sánz, Douglas Warner, Evangelos Terpos, Paul Cheng, Noopur Raje and Li Zhu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kamel Laribi

56 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

2018 307 citations Noopur Raje, Evangelos Terpos et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kamel Laribi France	17	606	604	336	329	321	62	1.2k
Ana Balanzategui Spain	25	459 0.8×	491 0.8×	440 1.3×	539 1.6×	492 1.5×	70	1.5k
Miguel Alcoceba Spain	21	442 0.7×	362 0.6×	322 1.0×	439 1.3×	460 1.4×	79	1.3k
Lorenzo Falchi United States	20	569 0.9×	257 0.4×	244 0.7×	707 2.1×	520 1.6×	113	1.3k
Jean Pierre Marolleau France	17	324 0.5×	263 0.4×	198 0.6×	397 1.2×	191 0.6×	53	977
Charalampia Kyriakou United Kingdom	14	436 0.7×	469 0.8×	312 0.9×	444 1.3×	323 1.0×	64	1.0k
Michele Merli Italy	17	329 0.5×	286 0.5×	303 0.9×	474 1.4×	705 2.2×	64	1.1k
Richard Delarue France	17	617 1.0×	191 0.3×	229 0.7×	922 2.8×	332 1.0×	47	1.2k
Kenton Wride United States	10	459 0.8×	1.4k 2.2×	626 1.9×	544 1.7×	838 2.6×	28	1.9k
Maria‐Christina Kyrtsonis Greece	16	298 0.5×	445 0.7×	259 0.8×	200 0.6×	252 0.8×	18	806
M. L. Vegna Italy	14	296 0.5×	765 1.3×	517 1.5×	186 0.6×	218 0.7×	20	1.2k

Countries citing papers authored by Kamel Laribi

Since Specialization

Citations

This map shows the geographic impact of Kamel Laribi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamel Laribi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamel Laribi more than expected).

Fields of papers citing papers by Kamel Laribi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamel Laribi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamel Laribi. The network helps show where Kamel Laribi may publish in the future.

Co-authorship network of co-authors of Kamel Laribi

This figure shows the co-authorship network connecting the top 25 collaborators of Kamel Laribi. A scholar is included among the top collaborators of Kamel Laribi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamel Laribi. Kamel Laribi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roos‐Weil, Damien, Cécile Tomowiak, Stéphanie Poulain, et al.. (2025). Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines. European Journal of Cancer. 232. 116120–116120.

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Laribi, Kamel, Stéphanie Poulain, Lise Willems, et al.. (2024). Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). British Journal of Haematology. 204(6). 2233–2236. 6 indexed citations

Macro, Margaret, Cyrille Hulin, Laure Vincent, et al.. (2023). Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study. Annals of Hematology. 102(8). 2137–2151. 6 indexed citations

Garciaz, Sylvain, Sarah Bertoli, David A. Sallman, et al.. (2023). Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study. Blood. 142(Supplement 1). 161–161. 7 indexed citations

Rennke, Helmut G., Marie Essig, Martin Carré, et al.. (2023). Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney International Reports. 8(12). 2733–2741. 2 indexed citations

Leblond, Véronique, Cécile Tomowiak, Kamel Laribi, et al.. (2022). Maladie de Waldenström : actualités et perspectives en 2022. Bulletin du Cancer. 110(1). 88–100. 1 indexed citations

Garciaz, Sylvain, Justine Decroocq, Sarah Bertoli, et al.. (2022). Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO). Blood. 140(Supplement 1). 6147–6148. 2 indexed citations

Herbaux, Charles, Stéphanie Poulain, Damien Roos‐Weil, et al.. (2021). Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab. Blood. 138(Supplement 1). 1201–1201. 5 indexed citations

10.

Toulon, Pierre, et al.. (2021). Acquired factor V inhibitor: Success of steroids in a patient with primary sclerosing cholangitis, ulcero haemorragic rectocolitis, biological Biermer's disease. Transfusion Clinique et Biologique. 28(2). 191–193. 2 indexed citations

11.

Wang, Eunice S., Pau Montesinos, Mark D. Minden, et al.. (2021). Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. Blood. 138(Supplement 1). 700–700. 16 indexed citations

12.

Ghesquières, Hervé, Olivier Casasnovas, Emmanuelle Nicolas‐Virelizier, et al.. (2021). Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma. Blood. 138(Supplement 1). 1370–1370. 1 indexed citations

13.

Laribi, Kamel, Alix Baugier de Materre, Mohamad Sobh, et al.. (2020). Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Advances. 4(19). 4838–4848. 41 indexed citations

14.

Laribi, Kamel, et al.. (2019). Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. Supportive Care in Cancer. 27(11). 4283–4292. 4 indexed citations

15.

Michallet, Anne‐Sophie, Melih Aktan, Wolfgang Hiddemann, et al.. (2018). Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 103(4). 698–706. 50 indexed citations

16.

Raje, Noopur, Evangelos Terpos, Wolfgang Willenbacher, et al.. (2018). Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet Oncology. 19(3). 370–381. 307 indexed citations breakdown →

17.

Laribi, Kamel, et al.. (2018). Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine. Experimental Hematology. 65. 34–37. 6 indexed citations

18.

Lemaire, Pierre, et al.. (2018). Shwachman-Diamond syndrome: a case report. Annales de biologie clinique. 76(4). 435–438. 1 indexed citations

19.

Laribi, Kamel, et al.. (2016). Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies. Biology of Blood and Marrow Transplantation. 22(8). 1357–1367. 37 indexed citations

20.

Laribi, Kamel, et al.. (2016). Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Annals of Hematology. 95(5). 765–769. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact